指南与共识技术与安全PETCT

韩国F-18 FDG躯干PET/CT有效剂量近期调查及PET/CT的CT协议当前推荐

Recent Survey of Effective Doses of F-18 FDG Torso PET/CT in Korea and the Current Recommendations for CT Protocols of PET/CT.
指南 / 共识 · Nucl Med Mol Imaging · 2020-07-20

该调查汇总韩国31家医院99名成人的F-18 FDG躯干PET/CT有效剂量与CT参数,按55、70、85 kg体重组分析。结果显示总有效剂量随体重增加而升高,采用超低剂量CT协议的医院其CT有效剂量在各体重组均显著低于低剂量CT组,迭代重建可进一步降低55 kg组的CT有效剂量。

要点

  • 55、70、85 kg组总有效剂量分别为8.77±2.76、10.93±3.14、12.57±3.79 mSv。
  • 54.5%的医院使用超低剂量CT协议,其CT有效剂量在各体重组均显著低于低剂量CT组(均p<0.001)。
  • 超低剂量CT组中,55 kg组使用迭代重建的CT有效剂量显著低于未使用迭代重建者(2.4±0.9 vs 3.3±0.9 mSv,p=0.04)。

诊断标准与关键数值

  • 55、70、85 kg组总有效剂量分别为8.77±2.76、10.93±3.14、12.57±3.79 mSv。
  • 55、70、85 kg组FDG有效剂量分别为4.80±0.98、6.05±1.15、6.89±1.52 mSv。
  • 55、70、85 kg组CT有效剂量分别为4.00±2.12、4.88±2.51、5.68±2.89 mSv。
  • 超低剂量CT组55、70、85 kg组CT有效剂量分别为2.9±1.0、3.2±1.1、3.3±1.0 mSv,低剂量CT组分别为6.6±1.6、7.2±2.1、7.9±2.2 mSv,超低剂量CT组均显著低于低剂量CT组(均p<0.001)。
  • 超低剂量CT组中55 kg组使用迭代重建的CT有效剂量为2.4±0.9 mSv,未使用迭代重建者为3.3±0.9 mSv,使用迭代重建者显著更低(p=0.04)。

临床应用与阅片要点

  • 调查显示54.5%的医院使用超低剂量CT协议,其CT有效剂量在各体重组均显著低于低剂量CT组。
  • 超低剂量CT组中55 kg组使用迭代重建的CT有效剂量显著低于未使用迭代重建者。
  • 作者认为这些结果和当前推荐有助于优化PET/CT诊断参考水平(DRL)并减少不必要的PET/CT辐射暴露。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to construct a database of the effective doses (ED) from F-18 fluorodeoxyglucose (FDG) torso positron emission tomography/computed tomography (PET/CT) in Korea to provide data that supports the reduction of the CT dose of PET/CT and optimization of PET/CT protocols in Korea.

METHODS: We investigated data of ED and CT parameters of FDG PET/CT. The data were analyzed by body weight groups.

RESULTS: A total of 31 hospitals participated in the survey (99 adults). The mean total EDs (± SD) were 8.77 ± 2.76, 10.93 ± 3.14, and 12.57 ± 3.79 mSv for the 55-, 70-, and 85-kg groups, respectively. The FDG EDs were 4.80 ± 0.98, 6.05 ± 1.15, and 6.89 ± 1.52 mSv, and the CT EDs were 4.00 ± 2.12, 4.88 ± 2.51, and 5.68 ± 2.89 mSv, respectively. Of the enrolled hospitals, 54.5% used ultra-low-dose CT protocols, and their CT ED was significantly lower than low-dose CT group in all groups (2.9 ± 1.0, 3.2 ± 1.1, and 3.3 ± 1.0 mSv vs. 6.6 ± 1.6, 7.2 ± 2.1, and 7.9 ± 2.2 mSv, all p < 0.001, respectively). In the ultra-low-dose CT group, the CT ED with the iterative reconstruction was significantly lower than that of CT without iterative reconstruction in the 55-kg group (2.4 ± 0.9 vs. 3.3 ± 0.9, p = 0.04).

CONCLUSIONS: These results and current recommendations can be helpful for optimizing PET/CT diagnostic reference level (DRL) and reducing unnecessary PET/CT radiation exposure.

来源:Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chong A, Park JM, Pak K, et al. Recent Survey of Effective Doses of F-18 FDG Torso PET/CT in Korea and the Current Recommendations for CT Protocols of PET/CT. Nucl Med Mol Imaging. 2020. PMID: 33088351. doi:10.1007/s13139-020-00654-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。